Anne Lesage Sells 3,700 Shares of Pharvaris (NASDAQ:PHVS) Stock

Key Points

• Insider Anne Lesage sold a total of 59,200 shares of Pharvaris during late April (Apr. 22–30), generating roughly $1.79 million in proceeds and reducing her stake in the company.
• Pharvaris stock fell about 5.1% to $29.44 on heavy trading (512,191 shares versus an average of 245,049), reflecting elevated market activity around the insider sales.
• Pharvaris is a clinical-stage biotech focused on hereditary angioedema with lead candidate PHA121, and Wall Street consensus is a "Moderate Buy" with an average target of about $42.73.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anne Lesage sold 3,700 shares of Pharvaris stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $30.08, for a total value of $111,296.00. Following the completion of the transaction, the insider owned 56,450 shares in the company, valued at approximately $1,698,016. This represents a 6.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Anne Lesage also recently made the following trade(s):

• On Thursday, April 30th, Anne Lesage sold 19,200 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total value of $580,992.00.
• On Thursday, April 30th, Anne Lesage sold 21,700 shares of Pharvaris stock. The shares were sold at an average price of $30.26, for a total value of $656,642.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,350.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,500 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $225,375.00.
• On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.

Pharvaris Stock Down 5.1%

NASDAQ:PHVS traded down $1.57 during mid-day trading on Friday, reaching $29.44. 512,191 shares of the company's stock traded hands, compared to its average volume of 245,049. Pharvaris N.V. has a 12-month low of $14.59 and a 12-month high of $31.14. The company has a 50 day moving average price of $27.62 and a 200-day moving average price of $26.03.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.15). Sell-side analysts anticipate that Pharvaris N.V. will post -3.19 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PHVS. Geode Capital Management LLC grew its holdings in shares of Pharvaris by 41.1% during the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company's stock worth $952,000 after acquiring an additional 15,769 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after acquiring an additional 783 shares during the period. Legal & General Group Plc grew its holdings in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock worth $203,000 after acquiring an additional 1,695 shares during the period. Amundi grew its holdings in shares of Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company's stock worth $489,000 after acquiring an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Pharvaris by 19.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company's stock worth $860,000 after acquiring an additional 7,879 shares during the period.

Wall Street Analysts Forecast Growth

PHVS has been the topic of a number of research analyst reports. Wedbush boosted their price target on Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a report on Tuesday, April 7th. HC Wainwright restated a "buy" rating and set a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Royal Bank Of Canada reduced their price target on Pharvaris from $52.00 to $51.00 and set an "outperform" rating on the stock in a report on Monday, April 6th. Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They set an "outperform" rating and a $42.00 price target on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a report on Tuesday, April 21st. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.73.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.